JAMA Medical News
New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions
June 18 · 22 min · 54.8 MB
0:00-22:49
Streams straight from the publisher. PodNod never proxies or re-hosts episode audio.
Rita Kalyani, MD, chief scientific and medical officer at the American Diabetes Association, discusses the latest diabetes and obesity research, including a novel oral GLP-1 drug, a combined semaglutide-amylin analogue injection, data from China on high-dose mazdutide, and more. Related Content: